May 29 Company Quick Takes: Priority Review for Amarin's Vascepa; plus Tuhura-Moffitt Cancer Center deal and more

Priority Review for Vascepa to reduce CV risk
Amarin Corp. plc (NASDAQ:AMRN) gained $1.98 (12%) to $18.99 on Wednesday after FDA accepted and granted

Read the full 236 word article

User Sign In